Table II.
Determination of the most effective non-steroidal anti-inflammatory drug in the treatment of ankylosing spondylitis.
| Agent | Change in pain score (%) | Change in PGA score (%) | Change in BASFI score (%) | ASAS20 (%) |
|---|---|---|---|---|
| Etoricoxib | 73.8 | 67.2 | 76.1 | 71.8 |
| Celecoxib | 0.19 | 0.00 | 0.58 | 0.22 |
| Meloxicam | 4.62 | 25.1 | NA | NA |
| Diclofenac | 4.28 | 2.06 | 3.54 | 1.53 |
| Naproxen | 11.8 | 2.10 | 12.1 | 2.62 |
| M2000 | 5.33 | 3.50 | 7.70 | 23.8 |
PGA, patient's global assessment of disease activity; BASFI, Bath Ankylosing Spondylitis Functional Index; ASAS20, Assessment in Ankylosing Spondylitis 20% response; NA, not available; M2000, beta-D-mannuronic acid.